The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy

1

Large B-cell lymphoma (LBCL) has poor outcomes in relapsed and refractory settings despite advancements in CD19 CAR-T immunotherapy.
2

Over half of patients with LBCL do not achieve durable remissions following CD19 CAR-T therapy, necessitating a better understanding of treatment resistance.
3

The tumor microenvironment (TME) plays a critical role in influencing clinical responses to CD19 CAR-T therapy in LBCL.
4

Emerging CAR-T engineering strategies aim to reprogram the immunosuppressive elements of the TME to improve treatment outcomes.
5

Advanced analytical approaches are required to integrate multimodal datasets for a comprehensive characterization of the LBCL TME.

1